Back to Authors

Baron, John A.

https://orcid.org/0000-0003-3461-1056

Mayo Clinic

University of North Carolina at Chapel Hill

Citations 34

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening
Poynter, Jenny N. , Weisenberger, Daniel J. , Long, Tiffany I. , Thibodeau, Stephen N. , Lindor, Noralane M. , Young, Joanne , Jenkins, Mark A. , Buchanan, Daniel D. , Levine, A. Joan, Gallinger, Steven, Bapat, Bharati , Potter, John D. , Haile, Robert W. , Investigators, for the Colon Cancer Family Registry, Siegmund, Kimberly D. , Hopper, John L. , Baron, John A. , Casey, Graham , Marchand, Loı̈c Le , Newcomb, Polly A. , Laird, Peter W. , Investigators, for the Colon Cancer Family Registry, Buchanan, Daniel D , Jenkins, Mark A , Haile, Robert W , Potter, John D

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3208-3215

10.1158/1055-9965.epi-08-0512 Get It

Abstract Microsatellite instability (MSI) occurs in 10% to 20% of colorectal cancers (CRC) and has been attributed to both MLH1 promoter hypermethylation and germline mutation in the mismatch repair (MMR) genes. We present results from a large population- and clinic-based study of MLH1 methylation, immunohistochemistry, and MMR germline mutations that enabled us to (a) estimate the prevalence of MMR germline mutations and MLH1 methylation among MSI-H cases and help us understand if all MSI-H CRC is explained by these mechanisms and (b) estimate the associations between MLH1 methylation and sex, age, and tumor location within the colon. MLH1 methylation was measured in 1,061 population-based and 172 clinic-based cases of CRC. Overall, we observed MLH1 methylation in 60% of population-based MSI-H cases and in 13% of clinic-based MSI-H cases. Within the population-based cases with MMR mutation screening and conclusive immunohistochemistry results, we identified a molecular event in MMR in 91% of MSI-H cases: 54% had MLH1 methylation, 14% had a germline mutation in a MMR gene, and 23% had immunohistochemistry evidence for loss of a MMR protein. We observed a striking age difference, with the prevalence of a MMR germline mutation more than 4-fold lower and the prevalence of MLH1 methylation more than 4-fold higher in cases diagnosed after the age of 50 years than in cases diagnosed before that age. We also determined that female sex is an independent predictor of MLH1 methylation within the MSI-H subgroup. These results reinforce the importance of distinguishing between the underlying causes of MSI in studies of etiology and prognosis. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3208–15)
Variants on 9p24 and 8q24 Are Associated with Risk of Colorectal Cancer: Results from the Colon Cancer Family Registry
Poynter, Jenny N. , Figueiredo, Jane C. , Conti, David V. , Kennedy, Kathleen , Gallinger, Steven , Thibodeau, Stephen N. , Jenkins, Mark A. , Byrnes, Graham , Goode, Ellen L. , Tiirikainen, Maarit , Lindor, Noralane M. , Grove, John, Jass, Jeremy R., Young, Joanne , Potter, John D. , Haile, Robert W. , Duggan, David , CFR, for the Colon, Siegmund, Kimberly D. , Casey, Graham , Hopper, John L. , Baron, John A. , Newcomb, Polly A. , Marchand, Loı̈c Le , CFR, for the Colon, Jenkins, Mark A , Haile, Robert W , Potter, John D , Conti, David V

Cancer Research | December 3, 2007 | Volume: 67 | Issue: 23 | Pages: 11128-11132

10.1158/0008-5472.can-07-3239 Get It

Abstract Recent publications have reported that common variants on 8q24 are associated with both prostate and colorectal cancers (CRC). In addition, one of these studies (the ARCTIC study) initially observed an association with a single nucleotide polymorphism (SNP) on 9p24 that was not confirmed in some of their validation data sets. In the research described here, we conducted a case-unaffected sibling analysis using population- and clinic-based discordant sibships (N = 1,567 sibships) from the Colon Cancer Family Registry (Colon CFR) to investigate the associations between common variants at 9p24 and 8q24 and risk of CRC. We also evaluated whether these associations differed by age, family history, and tumor characteristics, including microsatellite instability and tumor site. Associations were estimated using conditional logistic regression, treating sibship as the matching factor. Analyses were adjusted for age and sex, and stratified by ascertainment source (population versus clinic). We observed an association between a SNP on 9p24 (rs719725) and risk of CRC in the population-based series (AA versus CC: odds ratios, 1.46; 95% confidence interval, 1.06–2.02; AC versus CC: odds ratios, 1.50; 95% confidence interval, 1.14–1.98; P = 0.011 on 2 df). In the population-based series, we also detected statistically significant associations between two SNPs on 8q24, rs10505477 and rs6983267, and risk of CRC (P = 0.005 and P = 0.002, respectively). There was no evidence of statistically significant heterogeneity by age at diagnosis, family history of CRC, microsatellite instability, or tumor site at either locus and no evidence of interaction between SNPs on 8q24 and 9p24. These data suggest that common variants may play important roles in the risk of CRC. [Cancer Res 2007;67(23):11128–32]
Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer
Cotterchio, Michelle , Gallinger, Steve, Grove, John, Jass, Jeremy R., Lindor, Noralane M. , Potter, John D. , Templeton, Allyson , Thibodeau, S. N., Seminara, Daniela, Registry, for the Colon Cancer Family, Newcomb, Polly A. , Baron, John A. , Haile, Robert W. , Hall, David , Hopper, John L. , Marchand, Loı̈c Le , Limburg, Paul J. , Registry, for the Colon Cancer Family, Potter, John D

Cancer Epidemiology, Biomarkers & Prevention | November 15, 2007 | Volume: 16 | Issue: 11 | Pages: 2331-2343

10.1158/1055-9965.epi-07-0648 Get It

Abstract Background: Family studies have served as a cornerstone of genetic research on colorectal cancer. Materials and Methods: The Colorectal Cancer Family Registry (Colon CFR) is an international consortium of six centers in North America and Australia formed as a resource to support studies on the etiology, prevention, and clinical management of colorectal cancer. Differences in design and sampling schemes ensures a resource that covers the continuum of disease risk. Two separate recruitment strategies identified colorectal cancer cases: population-based (incident case probands identified by cancer registries; all six centers) and clinic-based (families with multiple cases of colorectal cancer presenting at cancer family clinics; three centers). At this time, the Colon CFR is in year 10 with the second phase of enrollment nearly complete. In phase I recruitment (1998-2002), population-based sampling ranged from all incident cases of colorectal cancer to a subsample based on age at diagnosis and/or family cancer history. During phase II (2002-2007), population-based recruitment targeted cases diagnosed before the age of 50 years are more likely attributable to genetic factors. Standardized protocols were used to collect information regarding family cancer history and colorectal cancer risk factors, and biospecimens were obtained to assess microsatellite instability (MSI) status, expression of mismatch repair proteins, and other molecular and genetic processes. Results: Of the 8,369 case probands enrolled to date, 2,602 reported having one or more colorectal cancer–affected relatives and 799 met the Amsterdam I criteria for Lynch syndrome. A large number of affected (1,324) and unaffected (19,816) relatives were enrolled, as were population-based (4,108) and spouse (983) controls. To date, 91% of case probands provided blood (or, for a few, buccal cell) samples and 75% provided tumor tissue. For a selected sample of high-risk subjects, lymphocytes have been immortalized. Nearly 600 case probands had more than two affected colorectal cancer relatives, and 800 meeting the Amsterdam I criteria and 128, the Amsterdam II criteria. MSI testing for 10 markers was attempted on all obtained tumors. Of the 4,011 tumors collected in phase I that were successfully tested, 16% were MSI-high, 12% were MSI-low, and 72% were microsatellite stable. Tumor tissues from clinic-based cases were twice as likely as population-based cases to be MSI-high (34% versus 17%). Seventeen percent of phase I proband tumors and 24% of phase II proband tumors had some loss of mismatch repair protein, with the prevalence depending on sampling. Active follow-up to update personal and family histories, new neoplasms, and deaths in probands and relatives is nearly complete. Conclusions: The Colon CFR supports an evolving research program that is broad and interdisciplinary. The greater scientific community has access to this large and well-characterized resource for studies of colorectal cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2331–43)
Accuracy of Colorectal Polyp Self-Reports: Findings from the Colon Cancer Family Registry
Madlensky, Lisa , Daftary, Darshana, Burnett, Terrilea, Harmon, Patricia, Jenkins, Mark A. , Maskiell, Judi, Nigon, Sandra, Phillips, Kerry, Templeton, Allyson , Haile, Robert W. , Potter, John D. , Gallinger, Steven, Limburg, Paul J. , Baron, John A. , Jenkins, Mark A , Haile, Robert W , Potter, John D

Cancer Epidemiology, Biomarkers & Prevention | September 13, 2007 | Volume: 16 | Issue: 9 | Pages: 1898-1901

10.1158/1055-9965.epi-07-0151 Get It

Abstract Introduction: Colorectal adenomas and other types of polyps are commonly used as end points or risk factors in epidemiologic studies. However, it is not known how accurately patients are able to self-report the presence or absence of adenomas following colonoscopy. Methods: Participants in the Colon Cancer Family Registry provided self-reports of recent colorectal cancer (CRC) screening activity, and whether or not they had ever been told they had a polyp. Positive and negative predictive values for polyp self-report were calculated by comparing medical records with self-reports from 488 participants. Results: The positive predictive value for self-reported polyp was 80.9%, and the negative predictive value was 85.8%. The predictive values did not differ by age group or sex, but participants with a previous diagnosis of CRC had a lower negative predictive value (76.2%) than participants with no personal history of CRC (89.0%; P = 0.04). Conclusions: Predictive values for self-reports of polyps are fairly high, but researchers needing accurate polyp data should obtain medical record confirmation. Pursuing medical records on only those participants self-reporting a polyp could result in an underestimation of the polyp prevalence in a study population. (Cancer Epidemiol Biomarkers Prev 2007;16(9):1898–901)